Klarquist Sparkman, LLP
Mesothelin domain-specific monoclonal antibodies and use thereof
Described herein is the use of rabbit hybridoma technology, along with a panel of truncated mesothelin domain fragments, to identify anti-mesothelin mAbs that bind specific regions of mesothelin. In one aspect of the present disclosure, the rabbit mAbs bind an epitope that is not part of Region I. In particular, the identified mAbs (YP187, YP223, YP218 and YP3) bind either Region II (391-486), Region III (487-581) or a native conformation of mesothelin with subnanomolar affinity. These antibodies do not compete for binding with the mesothelin-specific immunotoxin SS1P or mesothelin-specific antibody MORAb-009. In another aspect, disclosed is a high-affinity rabbit mAb that binds Region I of mesothelin (YP158). YP158 binds native mesothelin protein in cancer cells and tissues with high affinity and specificity.
The United States of America, as represented by the Secretary, Department of Health and Human Services
A A C C C C A G C C A A C A A C G C C C C G C A C A C C C A A C
A61K A61K C07K C07K C07K C07K A61K G01N C07K C07K A61K A61K C07K A61K A61K C07K G01N C07K C07K C07K C07K G01N C07K A61K C07K A61K C07K C07K C07K A61K A61K C07K
inventional inventional additional inventional additional additional inventional additional inventional additional inventional inventional additional inventional inventional additional inventional additional additional additional additional inventional additional inventional inventional inventional additional additional inventional inventional additional inventional
Ira H. Yen T. Yifan Raffit Wei Mitchell
Pastan Phung Zhang Hassan Gao Ho